$32.28
0.49%
Nasdaq, Nov 17, 04:00 pm EST. Closed.
ISIN
NL00150005Y4
Symbol
PHVS

Pharvaris NV Stock price

$32.28
+2.51 8.43% 1M
+3.47 12.04% 6M
+4.53 16.32% YTD
+7.36 29.53% 1Y
+16.13 99.88% 3Y
+17.12 112.93% 5Y
+12.28 61.40% 10Y
+12.28 61.40% 20Y
Nasdaq, Closing price Tue, Nov 17 2026
-0.16 0.49%
ISIN
NL00150005Y4
Symbol
PHVS
Industry

Is Pharvaris NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$2.3b
Enterprise Value
$1.9b
Net debt
positive
Cash
$350.0m
Shares outstanding
70.2m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
6.9
Financial Health
Equity Ratio
90.0%
Return on Equity
-64.8%
ROCE
-60.5%
ROIC
-2,018.6%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$23.0m | -
SBC as % of FCF
-
SBC Growth 1Y
7.2%
Share Count Growth 1Y
28.2%
Shareholder Yield
-28.2%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-199.9m
EBIT
$-200.5m
Net Income
$-187.9m
Free Cash Flow | ex SBC
$-170.7m | $-193.8m
Growth
Revenue | estimate
- | -
EBITDA
-10.1%
EBIT
-10.1%
Net Income
-1.6%
Free Cash Flow
-13.1%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-2.8
FCF per Share
$-2.4
Short interest
4.4%
Employees
134
Rev per Employee
$0.0

Pharvaris NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Pharvaris NV forecast:

20x Buy
95%
1x Hold
5%

Analyst Opinions

21 Analysts have issued a Pharvaris NV forecast:

Buy
95%
Hold
5%

Pharvaris NV Events

Past Events
NOV
12
Q3 2026 Earnings Call
5 days ago
SEP
15
Morgan Stanley 24th Annual Global Healthcare Conference
2 months ago
SEP
8
Special Call - Pharvaris N.V.
2 months ago
MAY
13
Bank of America Global Healthcare Conference 2026
6 months ago
DEC
3
Special Call - Pharvaris N.V.
12 months ago

Financial data from Pharvaris NV

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 58 58
11% 11%
-
- Research and Development Expense 142 142
10% 10%
-
-200 -200
10% 10%
-
- Depreciation and Amortization 0.54 0.54
42% 42%
-
EBIT (Operating Income) EBIT -200 -200
10% 10%
-
Net Profit -188 -188
2% 2%
-

In millions USD.

Don't miss a Thing! We will send you all news about Pharvaris NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pharvaris NV Stock News

Neutral
GlobeNewsWire
●
5 days ago
ZUG, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the oral and poster presentat...
Neutral
GlobeNewsWire
●
5 days ago
ZUG, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial res...
Neutral
GlobeNewsWire
●
about one month ago
ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results of RAPIDe-3, a ...
More Pharvaris NV News

Company Profile

Pharvaris NV is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Hans G. C. P. Schikan and Anne Lesage on September 30, 2015 and is headquartered in Leiden, Netherlands.

Head office Netherlands
CEO Mr. Modig
Employees 134
Founded 2015
Website pharvaris.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today